Tests AZD6750 alone and with other drugs in advanced solid tumors
Tests AZD6750, an IL-2 treatment, in adults with advanced solid cancers.
Plain-language title generated from the registry record
Registry title: A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Key facts
- Where
- East Melbourne, AustraliaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with certain advanced or metastatic solid tumors, such as melanoma, lung, kidney, head and neck, stomach, ovarian or triple negative breast cancer. They must have already had standard treatment.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Locally advanced or metastatic selected solid tumors. For the lung cancer part: Stage IV non-small cell lung cancer.
- Earlier treatment
- Must have had adequate standard treatment. Lung cancer: at least one earlier treatment for metastatic disease, or no earlier systemic therapy with PD-L1 of 1% or more. The expansion part takes only people with no earlier systemic therapy.
- Biomarker or test result
- Lung cancer without earlier systemic therapy: PD-L1 expression of 1% or more. Archival tumor sample needed.
Main reasons for not taking part
- Earlier organ or allogeneic stem cell transplant, or one planned
- Autoimmune or inflammatory disease in the past 3 years
- Brain metastases, unless treated, without symptoms and stable
- Active hepatitis B or hepatitis C infection
- Lung cancer part: earlier anti-TIGIT therapy
Read by machine on 9 November 2026.
Where in Australia
- East MelbourneEast Melbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07115043
- Record updated
- 8 October 2026
- Original description
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsRead full original descriptionShow less
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Inclusion: Participant ≥ 18 year; ECOG PS of 0 to 1; Provision of 'archival' tumor specimen; At least one measurable lesion according to RECIST v1.1,; Minimum life expectancy of 12 weeks; Adequate and stable cardiac function; Adequate bone marrow, liver and kidney function; Body weight ≥ 35 kg; Capable of giving signed informed consent; Module 1 specific inclusion criteria:; Participants with locally advanced or metastatic select solid tumors (MM, Squamous cell carcinoma of skin, MCC, NSCLC, Head and neck squamous cell carcinoma, Gastric cancer/gastroesophaegeal junction cancer, RCC, HGSOC, Triple negative breast cancer) who have received adequate SoC; Module 2 specific inclusion criteria:; Participants with Stage IV NSCLC Dose Escalation/Backfills; Have received at least one prior regimen in metastatic setting (2L+ NSCLC). Participants with actionable tumor alterations should have received targeted therapy if locally available OR; Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%; Dose Expansion; <!-- -->; Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.
Exclusion: History or planned organ or allogeneic stem cell transplantation; Active or prior documented autoimmune or inflammatory disorders, within the past 3 years; Any prior toxicities that led to permanent discontinuation of prior immunotherapy; Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy; Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids; Prior history of Grade ≥ 3 non-infectious pneumonitis; Participant requires chronic immunosuppressive therapy (including steroids > 10 mg prednisone/day or equivalent); Receipt of live attenuated vaccine within 30 days; Module 2 specific exclusion criteria:; Previous treatment with anti-TIGIT therapy; Any evidence of:; Severe or uncontrolled systemic diseases including respiratory, cardiac or tumor-related conditions; Acute untreated or symptomatic malignant spinal cord compression, or a history of leptomeningeal carcinomatosis; Active uncontrolled or chronic infection of hepatitis B, hepatitis C; 1L NSCLC participants with genetic alteration such as EGFR that has a targeted therapy in 1L as per local SoC.